ArticleOncogene2003
Activation of ErbB3-PI3-kinase pathway is correlated with malignant phenotypes of adenocarcinomas.
Article in Oncogene, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 43 citations in OpenAlex.
- Genomic Landscape of Poorly Differentiated Gastric Carcinoma: An AACR GENIELife (Basel, Switzerland) · 2026Article
- Prevalence of Her3 in gastric cancer and its association with molecular prognostic markers: a Saudi cohort based study.The Libyan journal of medicine · 2019Article
- The significance of scirrhous gastric cancer cell lines: the molecular characterization using cell lines and mouse models.Human cell · 2018Review
- Exploring Missense Mutations in Tyrosine Kinases Implicated with Neurodegeneration.Molecular neurobiology · 2017Review
- Signet-ring Cells in the Skin: A Case of Late-onset Cutaneous Metastasis of Gastric Carcinoma and a Brief Review of Histological Approach.Dermatology reports · 2016Article
- Immunohistochemical analysis of RTKs expression identified HER3 as a prognostic indicator of gastric cancer.Cancer science · 2014Article
- Clinical management of advanced gastric cancer: the role of new molecular drugs.World journal of gastroenterology · 2014Review
- Role of epidermal growth factor receptor in acute and chronic kidney injury.Kidney international · 2013Review
- Molecular targeted therapies in advanced gastric cancer: does tumor histology matter?Therapeutic advances in gastroenterology · 2013Article
- Immunoregulatory protein profiles of necrotizing enterocolitis versus spontaneous intestinal perforation in preterm infants.PloS one · 2012Article
- EGF and TGF-β1 Effects on Thyroid Function.Journal of thyroid research · 2011Article
- Genomic and epigenetic profiles of gastric cancer: potential diagnostic and therapeutic applications.Surgery today · 2011Review
- Heregulin β-1 induces loss of cell-cell contact and enhances expression of MUC1 at the cell surface in HCC2998 and MKN45-1 cells.PloS one · 2011Article
- Comparative study on overexpression of HER2/neu and HER3 in gastric cancer.World journal of surgery · 2009Article
- Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium.The Journal of clinical investigation · 2009Article
- ERBBs in the gastrointestinal tract: recent progress and new perspectives.Experimental cell research · 2009Review
- The ERBB3 receptor in cancer and cancer gene therapy.Cancer gene therapy · 2008Review
- The PI 3-kinase-Rac-p38 MAP kinase pathway is involved in the formation of signet-ring cell carcinoma.Oncogene · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Signet-ring cell carcinomas are malignant dedifferentiated carcinomas, which are frequently found in the stomach. We previously demonstrated that a 200 kDa protein is often constitutively phosphorylated on tyrosine and bound to phosphatidylinositol 3-kinase (PI3-kinase) in signet-ring cell carcinoma cells. In this study, we purified the 200 kDa protein from an extract of NUGC-4 cells, a cell line of signet-ring cell carcinoma, and identified it as ErbB3. ErbB3 was found to be phosphorylated selectively in dedifferentiated adenocarcinoma cell lines among various gastric cancer cell lines. Expression of a constitutively active chimeric receptor consisting of ErbB2 and ErbB3 in HCC2998 cells, a highly differentiated adenocarcinoma cell line, revealed that the signaling triggered by phosphorylation of ErbB3 was important for dedifferentiated phenotypes such as loss of cell-cell interaction and high expression of MUC1/DF3 antigen, a marker of the malignant tumors. Taken together, activation of ErbB3 pathway may contribute to the development of dedifferentiated carcinomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.